Anna L Godfrey

Anna L Godfrey

UNVERIFIED PROFILE

Are you Anna L Godfrey?   Register this Author

Register author
Anna L Godfrey

Anna L Godfrey

Publications by authors named "Anna L Godfrey"

Are you Anna L Godfrey?   Register this Author

18Publications

721Reads

14Profile Views

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

N Engl J Med 2018 10;379(15):1416-1430

From the Wellcome-MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research (J.G., C.E.M., F.L.N., A.R.G., P.J.C.), the Department of Haematology, University of Cambridge (J.G., E.J.B., C.M., J.C., C.E.M., F.L.N., A.R.G.), and the Department of Haematology, Cambridge University Hospitals NHS Foundation Trust (J.G., E.J.B., A.L.G., C.M., J.C., A.R.G.), Cambridge, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus (J.N., D.C.W., N.A., E.P., G.G., L.O., S.O., J.W.T., A.P.B., N.W., P.J.C.), and the European Molecular Biology Laboratory, European Bioinformatics Institute (R.C., M.G.), Hinxton, Big Data Institute, University of Oxford, Oxford (D.C.W.), the Department of Haematology, Queen's University Belfast, Belfast (M.F.M.), and the Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London (C.N.H.) - all in the United Kingdom; the Center for Molecular Oncology and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York (E.P., G.G.); the Department of Hematology, Zealand University Hospital, Roskilde, and the University of Copenhagen, Copenhagen (C.L.A., H.C.H.); and the Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy (P.G., A.M.V.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716614
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030948PMC
October 2018

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

J Clin Oncol 2018 Aug 28:JCO2018788414. Epub 2018 Aug 28.

Anna L. Godfrey, Jacob Grinfeld, and Anthony R. Green, Cambridge University Hospitals National Health Service (NHS) Foundation Trust; Peter J. Campbell and Jyoti Nangalia, Wellcome Trust Sanger Institute, Hinxton; Cathy MacLean, Julia Cook, Julie Temple, and Anthony R. Green, University of Cambridge; Anthony R. Green, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge; Georgina Buck, University of Oxford, Oxford; Bridget S. Wilkins and Claire N. Harrison, Guy's and St Thomas' NHS Foundation Trust, London; Keith Wheatley, University of Birmingham, Birmingham; Mary Frances McMullin, Queen's University Belfast, Belfast, United Kingdom; Cecily Forsyth, Gosford Hospital, Gosford, and Australasian Leukaemia and Lymphoma Group, Australia; and Jean-Jacques Kiladjian, Hôpital Saint-Louis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.8414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269131PMC
August 2018

After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.

Blood Rev 2017 05 15;31(3):101-118. Epub 2016 Nov 15.

Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Hills Rd, Cambridge CB2 0QQ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2016.11.001DOI Listing
May 2017

STAT1 activation in association with JAK2 exon 12 mutations.

Haematologica 2016 Jan 3;101(1):e15-9. Epub 2015 Dec 3.

Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, UK Department of Haematology, Addenbrooke's Hospital, UK Department of Haematology, University of Cambridge, Cambridge, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.128546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697901PMC
January 2016

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

Cell Rep 2015 Dec 10;13(11):2345-2352. Epub 2015 Dec 10.

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; Broad Institute of the Massachusetts Institute of Technology and Harvard, 415 Main Street, Cambridge, MA 02142; Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.11.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691544PMC
December 2015

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

Haematologica 2015 Nov 6;100(11):e438-42. Epub 2015 Aug 6.

Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK Department of Haematology, Addenbrooke's Hospital, Cambridge, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.129510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825297PMC
November 2015

Effect of mutation order on myeloproliferative neoplasms.

N Engl J Med 2015 Feb;372(7):601-612

Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Stem Cell Institute (C.A.O., D.G.K., J.N., Y.S., J.G., E.J.B., C.E.M., A.L.G., D.D., A.R.G.) and Department of Hematology (C.A.O., D.G.K., J.N., Y.S., J.G., E.J.B., C.E.M., A.L.G., D.D., G.S.V., P.J.C., A.R.G.), University of Cambridge, Department of Haematology, Addenbrooke's Hospital (C.A.O., J.N., J.G., E.J.B., A.L.G., G.S.V., P.J.C., A.R.G.), Wellcome Trust Sanger Institute (D.C.W., E.P., G.S.V., P.J.C.), and Cancer Research U.K. Cambridge Institute, Li Ka Shing Centre (S.M.), Cambridge, and Guy's and St. Thomas' National Health Service Foundation Trust, Guy's Hospital, London (C.N.H.) - all in the United Kingdom; Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Florence, Italy (P.G., A.V.); Departments of Pathology (B.B.) and Hematology (C.B.), Hospital del Mar, Barcelona; and the Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany (K.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1412098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660033PMC
February 2015

Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

Blood 2014 Nov;124(22):3332-4

Cambridge Institute for Medical Research and Wellcome Trust/Medical Research Council, Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge, United Kingdom Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-09-603043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239339PMC
November 2014

JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.

Proc Natl Acad Sci U S A 2014 Oct 6;111(42):15190-5. Epub 2014 Oct 6.

Cambridge Institute for Medical Research, Medical Research Council/Wellcome Trust Cambridge Stem Cell Institute, and Department of Haematology, University of Cambridge, Cambridge CB2 0XY, United Kingdom; Department of Haematology, Addenbrooke's Hospital, Cambridge CB2 0XY, United Kingdom; and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1401873111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210350PMC
October 2014

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

Blood 2014 May 1;123(20):3139-51. Epub 2014 Apr 1.

Cambridge Institute for Medical Research and Wellcome Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, United Kingdom; Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2013-06-51
Publisher Site
http://dx.doi.org/10.1182/blood-2013-06-510222DOI Listing
May 2014

Genotype-phenotype interactions in the myeloproliferative neoplasms.

Hematol Oncol Clin North Am 2012 Oct 28;26(5):993-1015. Epub 2012 Aug 28.

Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Hills Road, Cambridge CB2 0XY, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588120012
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2012.07.003DOI Listing
October 2012

In situ thrombolysis for cerebral venous thrombosis complicating anti-leukemic therapy.

Leuk Res 2011 Aug 27;35(8):1127-9. Epub 2011 Mar 27.

Department of Haematology, Addenbrooke's Hospital, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2011.02.014DOI Listing
August 2011

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Cancer Cell 2010 Nov;18(5):524-35

Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2010.10.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996868PMC
November 2010